RTTNews | Sep 16, 2021 07:31AM EDT

07:31 Thursday, September 16, 2021 (RTTNews.com) - Gilead Sciences, Inc. (GILD) reported new data from the phase 3 ASCENT study evaluating Trodelvy in patients with relapsed or refractory metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of them for metastatic disease. In this sub-analysis, Trodelvy improved progression-free survival, overall survival and objective response rate compared with chemotherapy chosen by the patients' physicians in patients who were not initially diagnosed with triple-negative breast cancer. The safety profile of Trodelvy in the subgroup was consistent with prior reports from the ASCENT study.

The new sub-analysis also showed significant and clinically meaningful improvements in health-related quality of life with Trodelvy.

Read the original article on RTTNews ( https://www.rttnews.com/3226229/gilead-new-data-shows-survival-benefit-with-trodelvy-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved